Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
Kate E Findeisen,1,* Julia Sewell,1,* Andrew JK Ostor2,3 1The Alfred Hospital, Melbourne, Victoria, Australia; 2Cabrini Medical Centre, Melbourne, Victoria, Australia; 3Monash University, Melbourne, Victoria, Australia*These authors contributed equally to this workCorresponde...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1232703be5704c69bbb462766b8c6605 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Kate E Findeisen,1,* Julia Sewell,1,* Andrew JK Ostor2,3 1The Alfred Hospital, Melbourne, Victoria, Australia; 2Cabrini Medical Centre, Melbourne, Victoria, Australia; 3Monash University, Melbourne, Victoria, Australia*These authors contributed equally to this workCorrespondence: Andrew JK OstorCabrini Medical Centre, Melbourne, Victoria, AustraliaTel +61 3 9509 4244Email andrewostor@gmail.comAbstract: Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines.Keywords: rheumatoid arthritis, biological therapies, bDMARDs |
|---|